Latest Asx Filings News

Boss Energy reported a sharp turnaround with a $34.2 million net loss for FY2025 despite generating $75.6 million in revenue, while withholding dividends amid ongoing challenges.

Metrics Master Income Trust (MXT) has announced a non-underwritten Unit Purchase Plan aiming to raise approximately A$120 million by offering new units to eligible unitholders in Australia and New Zealand.

Aspermont Limited has announced a Share Purchase Plan offering eligible shareholders the chance to buy new shares at a discounted price, aiming to raise up to $1.25 million. The offer opens on September 1 and closes mid-month, with trading expected to start by September 19.

Evolution Energy Minerals has disclosed a default notice from Tanzanian regulators over delayed mining commencement, yet remains confident in retaining its key graphite mining license.

PPK Group Limited reported a significant statutory loss for FY25, driven by a major non-cash impairment on its Li-S Energy investment, while its ballistic protection arm Craig International Ballistics delivered exceptional revenue growth.

Pentanet Limited has achieved its first full-year positive EBITDA of $1.4 million in FY25, driven by strong growth in its telecommunications and gaming segments, alongside strategic 5G network expansion and technology upgrades.

Echelon Resources reports a robust 34% revenue increase and 26% production growth for FY2025, driven by expanded stakes and drilling success at the Mereenie field. The company balances strong cash flow with strategic reinvestment and a modest dividend.

Adriatic Metals Plc shares have been suspended from the ASX to facilitate its proposed acquisition by Dundee Precious Metals Inc. under a UK scheme of arrangement.

Sparc Technologies reported a narrower FY25 loss alongside progress in green hydrogen and graphene additive projects, supported by government grants and a successful capital raise.

BNK Banking Corporation Limited has reported a significant turnaround in its FY25 financial results, driven by margin expansion and a robust capital position. The bank’s strategic portfolio reshaping and disciplined cost management underpin its improved profitability and outlook.

CI1 reported a sharp 57% revenue decline in FY25 but reduced its comprehensive loss by 64% through strategic disposals and capital returns. The company’s financial services operations in Australia and Singapore faced tough market conditions, prompting a portfolio reshaping.

PYC Therapeutics reported a 14.5% rise in income to AUD 26.17 million for FY2025 alongside a 33.3% increase in net loss, while increasing its stake in Vision Pharma to 97.1%. The auditor flagged material uncertainty over the company’s ability to continue as a going concern.